Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Enhertu (trastuzumab deruxtecan) and Lynparza (olaparib) for breast cancer settings.
Enhertu is being jointly developed and commercialized byAstraZeneca Plc(NASDAQ:AZN) andDaiichi Sankyo(OTC:DSNKY).
Lynparza is jointly developed and commercialized by AstraZeneca andMerck & Co Inc(NYSE:MRK).
Ipsen Buys Epizyme To Bolster Cancer Portfolio
Ipsen SA...
Login or create a forever free account to read this news
Sign up/Log in